Viewing data from:

CISATRACURIUM BESYLATE

ANDA

CISATRACURIUM BESYLATE | A211669 | MEITHEAL PHARMACEUTICALS INC

1 strength0 unique patents0 unique exclusivities

API Supply Chain9 active DMFs2 inactive

6 active API suppliers hold Drug Master Files for this ingredient.

GLAND PHARMA LTDCISATRACURIUM BESYLATE

DMF 229622009

TAPI NL BVCISATRACURIUM BESYLATE

DMF 231302009

WAVELENGTH ENTERPRISES LTDCISATRACURIUM BESYLATE

DMF 235542010

CF PHARMA LTDCISATRACURIUM BESYLATE VERSION FA1

DMF 249022012

CF PHARMA LTDCISATRACURIUM BESYLATE

DMF 249692012

FARMHISPANIA SACISATRACURIUM BESYLATE USP

DMF 249992011

GLAND PHARMA LTDCISATRACURIUM BESYLATE [PROCESS-II]

DMF 297382015

WAVELENGTH ENTERPRISES LTDCISATRACURIUM BESYLATE PROCESS B

DMF 391232024

NAVINTA LLCCISATRACURIUM BESYLATE USP

DMF 416042025

ALP PHARM BEIJING CO LTDInactiveCISATRACURIUM BESYLATE

DMF 240332010

ON DEMAND PHARMACEUTICALS INCInactiveCISATRACURIUM BESYLATE

DMF 405932025

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 29, 2019	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 2MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Apr 25, 2019

No patent or exclusivity listings for this strength.